


# **Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis**

Jitender Monga<sup>1</sup>, Dhatchayini Subramani<sup>1</sup>, Ajay Bharathan<sup>1</sup> and Jagadananda Ghosh<sup>1, 2, \*</sup>

<sup>1</sup> Vattikuti Urology Institute, <sup>2</sup>Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI 48202, United States.

\*Correspondence  
[jghosh1@hfhs.org](mailto:jghosh1@hfhs.org)

**Fig. 1D**



**Supplementary Figure 1.** Full-length scans of western blots. Black rectangles indicate regions used in figures.

Fig. 1E




Fig. 2A




Fig. 2B




Fig. 2D




Fig. 2E




Fig. 3E




Fig. 4B





Fig. 4F




Fig. 4F continue




Fig. 5A





Fig. 5B




Fig. 5B continue




Fig. 5C




Fig. 5C continue

